Pharmaceutical

Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis

Data support advancement of GS-6791 into clinical testing in patients with inflammatory diseases; first-in-human Phase 1 trial in healthy volunteers…

3 months ago

AccuStem Sciences and EmeritusDX Expand Blood-Based Testing Capabilities to Advance Cancer Diagnostics and Treatment Planning

PHOENIX, Ariz. and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company…

3 months ago

Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress

New analysis of ZORYVE foam 0.3% demonstrates reduction in signs and symptoms of seborrheic dermatitis in individuals with diverse skin…

3 months ago

ALK and GenSci partner to expand the AIT market in China

Inside Information GenSci is granted exclusive rights to ALK’s house dust mite AIT products in China. ALK will be eligible…

3 months ago

Hemogenyx Pharmaceuticals PLC Announces Third Patient Safety

Third Patient Treated with HG-CT-1 CAR-T Therapy Successfully Passes Initial Safety Evaluation LONDON, UNITED KINGDOM / ACCESS Newswire / September…

3 months ago

Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025

- Abstract highlights additional primary and secondary data from Phase 3 STAR-1 clinical study of XYNGARI™ for the treatment of…

3 months ago

Optigenex Inc. Reports Positive Results in a Group of Human Subjects with Normal Cognitive Function, in a Double-Blind, Cross Over, Placebo Controlled, Randomized Cognitive Study with ac-11(R)

Study Sponsored by Optigenex Inc. and conducted by the University of Northern Arizona led by Doctor Oneil Guthrie, demonstrates significant…

3 months ago

E Tech Group to Introduce Vendor-Neutral LAIR Platform at ISPE Boston 2025

E Tech Group will introduce its Laboratory Automation and Industrial Robotics (LAIR) workflow orchestration platform at the ISPE Boston Area…

3 months ago

Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025

DENVER, CO / ACCESS Newswire / September 16, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical…

3 months ago